May 2021

There is no evidence of benefit from testosterone replacement therapy in chronic disease, ageing or obesity, and no justification for trialling it. A definitive diagnosis of hypogonadism is required before starting and carefully monitoring lifelong therapy.

People who have sustained a minimal trauma fracture are at increased risk of secondary fractures. A systematic, co-ordinated approach is key to secondary fracture prevention and involves risk factor assessment and use of pharmacological and nonpharmacological therapies.